The FDA issued warning letters to 30 telehealth companies on March 3 for making false and misleading claims about compounded GLP-1 weight-loss drugs, marking the agency's most aggressive enforcement action against the booming compounded semaglutide market [1].

The letters targeted companies that marketed compounded versions of semaglutide and tirzepatide as equivalent to FDA-approved products like Wegovy and Mounjaro. The FDA emphasized that compounded drugs are not FDA-approved and that claims implying equivalence are illegal [2]. Companies including Hims & Hers were among those that received warnings, according to STAT News reporting [3].

The crackdown follows a February executive action in which the FDA signaled it intended to take action against non-FDA-approved GLP-1 drugs broadly [4]. The compounded GLP-1 market grew rapidly during drug shortages in 2024 and 2025, when 503A and 503B pharmacies filled a supply gap for patients who could not access brand-name products.

Corporate counsel analysis from Law.com noted that the warning letters put pressure on both compounders and the telehealth platforms that prescribe and market their products [5]. The FDA commissioner described the action as opening "a new era of enforcement."

The regulatory tightening arrives as branded GLP-1 supply has improved significantly, with the Wegovy pill launching in January and Eli Lilly expanding Mounjaro production. For the telehealth companies that built businesses around compounded alternatives, the warning letters signal that the window is closing.

-- Nora Whitfield, Washington